- Home
- CET vs SNDX Comparison
CET vs SNDX Comparison
Compare CET & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- SNDX
- Stock Information
- Founded
- CET 1929
- SNDX 2005
- Country
- CET United States
- SNDX United States
- Employees
- CET N/A
- SNDX N/A
- Industry
- CET Finance/Investors Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- SNDX Health Care
- Exchange
- CET Nasdaq
- SNDX Nasdaq
- Market Cap
- CET 1.5B
- SNDX 1.3B
- IPO Year
- CET N/A
- SNDX 2016
- Fundamental
- Price
- CET $51.69
- SNDX $13.22
- Analyst Decision
- CET
- SNDX Strong Buy
- Analyst Count
- CET 0
- SNDX 11
- Target Price
- CET N/A
- SNDX $38.55
- AVG Volume (30 Days)
- CET 38.4K
- SNDX 3.4M
- Earning Date
- CET 01-01-0001
- SNDX 11-03-2025
- Dividend Yield
- CET 4.50%
- SNDX N/A
- EPS Growth
- CET N/A
- SNDX N/A
- EPS
- CET 7.40
- SNDX N/A
- Revenue
- CET $27,062,484.00
- SNDX $77,933,000.00
- Revenue This Year
- CET N/A
- SNDX $629.90
- Revenue Next Year
- CET N/A
- SNDX $114.74
- P/E Ratio
- CET $6.90
- SNDX N/A
- Revenue Growth
- CET 15.78
- SNDX 2126.66
- 52 Week Low
- CET $40.24
- SNDX $8.58
- 52 Week High
- CET $52.42
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- CET 50.08
- SNDX 34.75
- Support Level
- CET $50.26
- SNDX $13.00
- Resistance Level
- CET $52.00
- SNDX $15.79
- Average True Range (ATR)
- CET 0.86
- SNDX 1.09
- MACD
- CET -0.03
- SNDX -0.27
- Stochastic Oscillator
- CET 47.35
- SNDX 6.32
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.